Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international database used to track cases of COVID-19 in patients with inflammatory bowel disease. Browse the resources below for important updates, and to learn more about COVID-19's impact on the IBD community.


Video Length 00:51:53

Updates on COVID-19 Research: SECURE-IBD & IBD Partners In this video, we are joined by Drs. Mike Kappelman and Millie Long from the University of North Carolina at Chapel Hill for an update on the findings from SECURE-IBD, and learn more about other research efforts that are ongoing to better understand the impact of COVID-19 on IBD patients.

Slides from the presentation above can be viewed and downloaded here.

SECURE-IBD updates

As of May 12th, healthcare professionals from around the world (42 different countries) have reported a total of 1074 cases of confirmed COVID-19 in IBD patients. View the web-based interactive map that visually represents the SECURE-IBD data.

More information, including a breakdown of cases by age, gender, disease type, comorbidities, and medication use, is also publicly available at www.covidibd.org. Advancing age, number of comorbidities, and smoking status continue to be the major drivers of COVID-19 related mortality and other indicators of a more severe disease course. Oral steroid use continues to be the largest medication-associated risk factor.

Who is organizing this project?

This project is being led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill and Dr. Ryan Ungaro (Gastroenterologist) and Dr. Jean-Frederic Colombel (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

Are there any partnering organizations/societies?

Official partners include the Crohn’s & Colitis Foundation, the International Organization for the Study of IBD (IOIBD), the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Crohn’s and Colitis Organisation (ECCO), the Asian Organization for Crohn’s & Colitis, and the Pan American Crohn's and Colitis Organisation (PANCCO). We also acknowledge the promotional support of many local/regional societies and pharmaceutical companies as detailed on www.covidibd.org.